Direct cost analysis of the second year post-allogeneic hematopoietic stem cell transplantation in the Bone Marrow Transplant Centre of Tunisia
Background: Hematopoietic stem cell transplantation (HSCT) is a medically complicated therapy with a long recovery time. In Tunisia, the National Health Insurance Fund (CNAM) covers only the first year post-transplantation, after which the costs are borne by the hospital. Objective: Describe complic...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2017-01-01
|
| Series: | Journal of Market Access & Health Policy |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/20016689.2017.1335161 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850241727811551232 |
|---|---|
| author | Myriam Razgallah Khrouf Leila Achour Asma Thabti Mohamed Ali Soussi Nour Abdejelil Olfa Lazreg Chema Drira Aida Zahaf Saloua Ladab Tarek Ben Othman |
| author_facet | Myriam Razgallah Khrouf Leila Achour Asma Thabti Mohamed Ali Soussi Nour Abdejelil Olfa Lazreg Chema Drira Aida Zahaf Saloua Ladab Tarek Ben Othman |
| author_sort | Myriam Razgallah Khrouf |
| collection | DOAJ |
| description | Background: Hematopoietic stem cell transplantation (HSCT) is a medically complicated therapy with a long recovery time. In Tunisia, the National Health Insurance Fund (CNAM) covers only the first year post-transplantation, after which the costs are borne by the hospital. Objective: Describe complications that can occur during the second year post-allogeneic HSCT and calculate direct costs in different groups of patients. Methods: In this pharmacoeconomic study, medical records of the second year post-allogeneic HSCT were collected. Studied variables included frequent observed complications and medical and non-medical direct costs. Results: The average total direct cost in the population during the second year post-transplantation was $11,571, 97% of which represents direct medical costs Drugs accounted for the largest share (80%) of total direct costs, dominated by the cost of antifungals (52%) and antivirals (26%) drug . Cytomegalovirus status was seen in 9.3% of patients and was associated with a seven-fold increase in direct costs (p < 0.001).In patients who developed chronic GVHD, the average direct cost was three times higher than for those who did not (p = 0.032). Conclusion: Given the importance of direct costs in the post-transplantation period a review of the hospital financing mechanism and a new convention with the CNAM is crucial. |
| format | Article |
| id | doaj-art-bd1f0157bcfa4792a753ad867b6754ac |
| institution | OA Journals |
| issn | 2001-6689 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Market Access & Health Policy |
| spelling | doaj-art-bd1f0157bcfa4792a753ad867b6754ac2025-08-20T02:00:30ZengMDPI AGJournal of Market Access & Health Policy2001-66892017-01-015110.1080/20016689.2017.13351611335161Direct cost analysis of the second year post-allogeneic hematopoietic stem cell transplantation in the Bone Marrow Transplant Centre of TunisiaMyriam Razgallah Khrouf0Leila Achour1Asma Thabti2Mohamed Ali Soussi3Nour Abdejelil4Olfa Lazreg5Chema Drira6Aida Zahaf7Saloua Ladab8Tarek Ben Othman9Centre National de Greffe de Moelle OsseuseCentre National de Greffe de Moelle OsseuseCentre National de Greffe de Moelle OsseuseCentre National de Greffe de Moelle OsseuseCentre National de Greffe de Moelle OsseuseCentre National de Greffe de Moelle OsseuseCentre National de Greffe de Moelle OsseuseCentre National de Greffe de Moelle OsseuseCentre National de Greffe de Moelle OsseuseCentre National de Greffe de Moelle OsseuseBackground: Hematopoietic stem cell transplantation (HSCT) is a medically complicated therapy with a long recovery time. In Tunisia, the National Health Insurance Fund (CNAM) covers only the first year post-transplantation, after which the costs are borne by the hospital. Objective: Describe complications that can occur during the second year post-allogeneic HSCT and calculate direct costs in different groups of patients. Methods: In this pharmacoeconomic study, medical records of the second year post-allogeneic HSCT were collected. Studied variables included frequent observed complications and medical and non-medical direct costs. Results: The average total direct cost in the population during the second year post-transplantation was $11,571, 97% of which represents direct medical costs Drugs accounted for the largest share (80%) of total direct costs, dominated by the cost of antifungals (52%) and antivirals (26%) drug . Cytomegalovirus status was seen in 9.3% of patients and was associated with a seven-fold increase in direct costs (p < 0.001).In patients who developed chronic GVHD, the average direct cost was three times higher than for those who did not (p = 0.032). Conclusion: Given the importance of direct costs in the post-transplantation period a review of the hospital financing mechanism and a new convention with the CNAM is crucial.http://dx.doi.org/10.1080/20016689.2017.1335161Allogeneic stem cell transplantationcomplicationscostpharmacoeconomic |
| spellingShingle | Myriam Razgallah Khrouf Leila Achour Asma Thabti Mohamed Ali Soussi Nour Abdejelil Olfa Lazreg Chema Drira Aida Zahaf Saloua Ladab Tarek Ben Othman Direct cost analysis of the second year post-allogeneic hematopoietic stem cell transplantation in the Bone Marrow Transplant Centre of Tunisia Journal of Market Access & Health Policy Allogeneic stem cell transplantation complications cost pharmacoeconomic |
| title | Direct cost analysis of the second year post-allogeneic hematopoietic stem cell transplantation in the Bone Marrow Transplant Centre of Tunisia |
| title_full | Direct cost analysis of the second year post-allogeneic hematopoietic stem cell transplantation in the Bone Marrow Transplant Centre of Tunisia |
| title_fullStr | Direct cost analysis of the second year post-allogeneic hematopoietic stem cell transplantation in the Bone Marrow Transplant Centre of Tunisia |
| title_full_unstemmed | Direct cost analysis of the second year post-allogeneic hematopoietic stem cell transplantation in the Bone Marrow Transplant Centre of Tunisia |
| title_short | Direct cost analysis of the second year post-allogeneic hematopoietic stem cell transplantation in the Bone Marrow Transplant Centre of Tunisia |
| title_sort | direct cost analysis of the second year post allogeneic hematopoietic stem cell transplantation in the bone marrow transplant centre of tunisia |
| topic | Allogeneic stem cell transplantation complications cost pharmacoeconomic |
| url | http://dx.doi.org/10.1080/20016689.2017.1335161 |
| work_keys_str_mv | AT myriamrazgallahkhrouf directcostanalysisofthesecondyearpostallogeneichematopoieticstemcelltransplantationinthebonemarrowtransplantcentreoftunisia AT leilaachour directcostanalysisofthesecondyearpostallogeneichematopoieticstemcelltransplantationinthebonemarrowtransplantcentreoftunisia AT asmathabti directcostanalysisofthesecondyearpostallogeneichematopoieticstemcelltransplantationinthebonemarrowtransplantcentreoftunisia AT mohamedalisoussi directcostanalysisofthesecondyearpostallogeneichematopoieticstemcelltransplantationinthebonemarrowtransplantcentreoftunisia AT nourabdejelil directcostanalysisofthesecondyearpostallogeneichematopoieticstemcelltransplantationinthebonemarrowtransplantcentreoftunisia AT olfalazreg directcostanalysisofthesecondyearpostallogeneichematopoieticstemcelltransplantationinthebonemarrowtransplantcentreoftunisia AT chemadrira directcostanalysisofthesecondyearpostallogeneichematopoieticstemcelltransplantationinthebonemarrowtransplantcentreoftunisia AT aidazahaf directcostanalysisofthesecondyearpostallogeneichematopoieticstemcelltransplantationinthebonemarrowtransplantcentreoftunisia AT saloualadab directcostanalysisofthesecondyearpostallogeneichematopoieticstemcelltransplantationinthebonemarrowtransplantcentreoftunisia AT tarekbenothman directcostanalysisofthesecondyearpostallogeneichematopoieticstemcelltransplantationinthebonemarrowtransplantcentreoftunisia |